Inotersen therapy of transthyretin amyloid cardiomyopathy

Research output: Contribution to journalArticle

Abstract

Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy. Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness (Formula presented.) 1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Safety and cardiac structural and functional parameters were prospectively studied. Results: As of October 2018, 33 subjects have entered the study. Twenty have completed 1 year, 16 have completed 2 years, and 14 have completed three years. At the 2 year time point, mean LV mass decreased by 8.4% as measured by MRI, and exercise tolerance increased by 20.2 metres as measured by 6 minute walk test. Further positive indicators were noted at 3 years, with LV mass decreasing by 11.4% and 6MWT increasing by 16.2 metres. Conclusion: Long term treatment of amyloid cardiomyopathy with inotersen is safe and effective in inhibiting progression and potentially reversing amyloid burden.

Original languageEnglish (US)
JournalAmyloid
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Prealbumin
Cardiomyopathies
Amyloid
Therapeutics
Safety
Exercise Tolerance
Antisense Oligonucleotides
Cause of Death
Heart Failure
Liver

Keywords

  • amyloidosis
  • cardiomyopathy
  • inotersen
  • Transthyretin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Inotersen therapy of transthyretin amyloid cardiomyopathy. / Dasgupta, Noel R.; Rissing, Stacy M.; Smith, Jessica; Jung, Jeesun; Benson, Merrill D.

In: Amyloid, 01.01.2019.

Research output: Contribution to journalArticle

@article{4e793a85ccc74f34a05b39021d47cff9,
title = "Inotersen therapy of transthyretin amyloid cardiomyopathy",
abstract = "Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy. Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness (Formula presented.) 1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Safety and cardiac structural and functional parameters were prospectively studied. Results: As of October 2018, 33 subjects have entered the study. Twenty have completed 1 year, 16 have completed 2 years, and 14 have completed three years. At the 2 year time point, mean LV mass decreased by 8.4{\%} as measured by MRI, and exercise tolerance increased by 20.2 metres as measured by 6 minute walk test. Further positive indicators were noted at 3 years, with LV mass decreasing by 11.4{\%} and 6MWT increasing by 16.2 metres. Conclusion: Long term treatment of amyloid cardiomyopathy with inotersen is safe and effective in inhibiting progression and potentially reversing amyloid burden.",
keywords = "amyloidosis, cardiomyopathy, inotersen, Transthyretin",
author = "Dasgupta, {Noel R.} and Rissing, {Stacy M.} and Jessica Smith and Jeesun Jung and Benson, {Merrill D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/13506129.2019.1685487",
language = "English (US)",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Inotersen therapy of transthyretin amyloid cardiomyopathy

AU - Dasgupta, Noel R.

AU - Rissing, Stacy M.

AU - Smith, Jessica

AU - Jung, Jeesun

AU - Benson, Merrill D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy. Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness (Formula presented.) 1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Safety and cardiac structural and functional parameters were prospectively studied. Results: As of October 2018, 33 subjects have entered the study. Twenty have completed 1 year, 16 have completed 2 years, and 14 have completed three years. At the 2 year time point, mean LV mass decreased by 8.4% as measured by MRI, and exercise tolerance increased by 20.2 metres as measured by 6 minute walk test. Further positive indicators were noted at 3 years, with LV mass decreasing by 11.4% and 6MWT increasing by 16.2 metres. Conclusion: Long term treatment of amyloid cardiomyopathy with inotersen is safe and effective in inhibiting progression and potentially reversing amyloid burden.

AB - Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy. Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness (Formula presented.) 1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Safety and cardiac structural and functional parameters were prospectively studied. Results: As of October 2018, 33 subjects have entered the study. Twenty have completed 1 year, 16 have completed 2 years, and 14 have completed three years. At the 2 year time point, mean LV mass decreased by 8.4% as measured by MRI, and exercise tolerance increased by 20.2 metres as measured by 6 minute walk test. Further positive indicators were noted at 3 years, with LV mass decreasing by 11.4% and 6MWT increasing by 16.2 metres. Conclusion: Long term treatment of amyloid cardiomyopathy with inotersen is safe and effective in inhibiting progression and potentially reversing amyloid burden.

KW - amyloidosis

KW - cardiomyopathy

KW - inotersen

KW - Transthyretin

UR - http://www.scopus.com/inward/record.url?scp=85074991773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074991773&partnerID=8YFLogxK

U2 - 10.1080/13506129.2019.1685487

DO - 10.1080/13506129.2019.1685487

M3 - Article

C2 - 31713445

AN - SCOPUS:85074991773

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

ER -